Active specific adjuvant immunotherapy with vaccinia melanoma oncolysate

Ann Plast Surg. 1992 Jan;28(1):108-9. doi: 10.1097/00000637-199201000-00027.

Abstract

Vaccinia melanoma oncolysate is an investigative agent for active specific adjuvant immunotherapy. Viral oncolysate work in animals has led to application of this treatment in humans. Success of initial trials in treatment of melanoma has led to a phase III randomized, prospective, double-blind, multi-institutional trial, which is currently under way.

Publication types

  • Review

MeSH terms

  • Adjuvants, Immunologic / administration & dosage
  • Adjuvants, Immunologic / pharmacology
  • Adjuvants, Immunologic / therapeutic use*
  • Animals
  • Antigens, Neoplasm / therapeutic use*
  • Antigens, Viral / therapeutic use*
  • Cell Membrane / immunology
  • Drug Evaluation, Preclinical
  • Humans
  • Immunotherapy, Active / methods
  • Immunotherapy, Active / standards*
  • Melanoma / immunology
  • Melanoma / mortality
  • Melanoma / therapy*
  • Randomized Controlled Trials as Topic
  • Skin Neoplasms / immunology
  • Skin Neoplasms / mortality
  • Skin Neoplasms / therapy*
  • Survival Rate
  • Vaccinia virus / immunology*

Substances

  • Adjuvants, Immunologic
  • Antigens, Neoplasm
  • Antigens, Viral